Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Differential Diagnosis of Borderline Ovarian Tumors from Stage I Malignant Ovarian Tumors using FDG PET/CT

Differential Diagnosis of Borderline Ovarian Tumors from Stage I Malignant Ovarian Tumors using... Nucl Med Mol Imaging (2013) 47:81–88 DOI 10.1007/s13139-013-0197-5 ORIGINAL ARTICLE Differential Diagnosis of Borderline Ovarian Tumors from Stage I Malignant Ovarian Tumors using FDG PET/CT Chulhan Kim & Hyun Hoon Chung & So Won Oh & Keon Wook Kang & June-Key Chung & Dong Soo Lee Received: 7 November 2012 /Revised: 24 February 2013 /Accepted: 5 March 2013 /Published online: 4 April 2013 Korean Society of Nuclear Medicine 2013 Abstract was comprised of three endometrioid, two clear cell and one Purpose Borderline ovarian tumors (BOTs) are more mucinous tumors. Among the comparisons between two common in young women of reproductive age, and groups, SUV of the BOT group was significantly lower max exhibit a better prognosis than malignant ovarian tu- than that of the MOT group (2.9±1.5 vs. 6.6±2.9, p=0. mors (MOTs). Fluorodeoxyglucose (FDG) positron 0223); otherwise, no significant difference was found in age, emission tomography/computed tomography (PET/CT) CA-125, diameter, or MTV. By receiver-operating charac- were compared in their ability to differentiate BOTs teristic curve analysis, SUV of 3.7 was the best cutoff max from stage I MOTs. value to differentiate BOTs from stage I MOTs, with a Methods Among 173 patients who had preoperative FDG sensitivity of 83.3 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Nuclear Medicine and Molecular Imaging Springer Journals

Differential Diagnosis of Borderline Ovarian Tumors from Stage I Malignant Ovarian Tumors using FDG PET/CT

Download PDF
8 pages

Loading next page...
 
/lp/springer-journals/differential-diagnosis-of-borderline-ovarian-tumors-from-stage-i-eiyS5BEgCg

References (28)

Publisher
Springer Journals
Copyright
Copyright © 2013 by Korean Society of Nuclear Medicine
Subject
Medicine & Public Health; Nuclear Medicine; Imaging / Radiology; Orthopedics; Cardiology; Oncology
ISSN
1869-3474
eISSN
1869-3482
DOI
10.1007/s13139-013-0197-5
pmid
24900087
Publisher site
See Article on Publisher Site

Abstract

Nucl Med Mol Imaging (2013) 47:81–88 DOI 10.1007/s13139-013-0197-5 ORIGINAL ARTICLE Differential Diagnosis of Borderline Ovarian Tumors from Stage I Malignant Ovarian Tumors using FDG PET/CT Chulhan Kim & Hyun Hoon Chung & So Won Oh & Keon Wook Kang & June-Key Chung & Dong Soo Lee Received: 7 November 2012 /Revised: 24 February 2013 /Accepted: 5 March 2013 /Published online: 4 April 2013 Korean Society of Nuclear Medicine 2013 Abstract was comprised of three endometrioid, two clear cell and one Purpose Borderline ovarian tumors (BOTs) are more mucinous tumors. Among the comparisons between two common in young women of reproductive age, and groups, SUV of the BOT group was significantly lower max exhibit a better prognosis than malignant ovarian tu- than that of the MOT group (2.9±1.5 vs. 6.6±2.9, p=0. mors (MOTs). Fluorodeoxyglucose (FDG) positron 0223); otherwise, no significant difference was found in age, emission tomography/computed tomography (PET/CT) CA-125, diameter, or MTV. By receiver-operating charac- were compared in their ability to differentiate BOTs teristic curve analysis, SUV of 3.7 was the best cutoff max from stage I MOTs. value to differentiate BOTs from stage I MOTs, with a Methods Among 173 patients who had preoperative FDG sensitivity of 83.3

Journal

Nuclear Medicine and Molecular Imaging – Springer Journals

Published: Apr 4, 2013

There are no references for this article.